However, given the published data to date, overall activity of anti-CTLA-4 and anti-PD-1/PD-L1 agents in advanced uveal melanoma is limited and should not be used in frontline treatment as it stands in cutaneous melanoma. Here, PDCD1 is linked to cutaneous melanoma.